For full functionality of this page it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser Pharmaceutical Industry Category Archives
US Flag
UK Flag Canada Flag

Category: Pharmaceutical Industry

Sep
23

What The FDA’s Nitrosamine Impurity Guidance Means for Drug Manufacturers

It’s been over two years since carcinogenic nitrosamines were discovered in some widely used drugs. The discovery occurred in 2018 when the contaminant was found in active pharmaceutical ingredients in Valsartan, a blood pressure medication. Since then, the contaminant has been found in several other drugs taken by millions of people each year. The Latest Update In 2019, the contaminant was found in ranitidine medications (commonly known as Zantac) and Nizatidine.

Continue Reading
Jul
17

The FDA Resumes Its Random Inspections. Are You Prepared?

The FDA recently announced that its inspectors may be knocking on your door as early as July 20 to conduct long-overdue domestic inspections. Once given the green light, inspectors’ first priority will be to conduct “mission critical” inspections of facilities considered to be of highest risk.

Continue Reading
Jun
01

Drug Recall Risks During – and After – a Global Pandemic

Until a few months ago, few if any senior executives had personal experience managing a company during a pandemic. Making matters more difficult, there’s really no recent history to consult to determine what perils lie ahead, which processes worked, which didn’t, and how to plan for a recovery once the crisis passes. Unfortunately, this uncertain environment seems likely to continue for the foreseeable future.

Continue Reading
Mar
19

Recalls During the COVID-19 Pandemic

First and foremost, we hope you and everyone close to you are well. We’re living through an unprecedented time and hopefully you’re able to find some calm and maintain connections. Like each of you, we’ve been working through the COVID-19 crisis, encouraging workers to follow the recommendations of federal, state and local health officials. But as crisis management professionals, we also can’t help but think about the long game.

Continue Reading
Mar
18

Future Cost of COVID-19 on Pharma Manufacturers

As the number of COVID-19 cases continue to increase worldwide, numerous questions and a tremendous amount of misinformation cloud the issue. Many remain confused about how the virus is transmitted, how dangerous it is, and what treatments for it may be available. The good news is that the safety of our food has been given a clean bill of health so far. Research indicates that food and food ingredients aren’t a transfer source for coronavirus.

Continue Reading